Navrogen Enters into CRADA with the U.S. National Cancer Institute to Develop Agents to Overcome Tumor-Mediated Immunosuppression
Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI). The CRADA is focused...
Read More
September 17, 2019
Navrogen Announces the Closing of $3.2M Funding to Support its Humoral Immuno-Oncology Platform Discovery Technologies and Preclinical Pipeline
Navrogen, Inc. announced today that it has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. The financing...
